TREATMENT OPTIONS FOR TYPE 2 DIABETES IN ADOLESCENTS AND YOUTH (TODAY)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 今天的试验是一项比较实验，主要目的是在10至17岁的T2 DM患者中，基于血糖控制，比较三种治疗方案在治疗失败方面的及时疗效。审判将由三个方面组成。这三个治疗组的比较是：(1)单用二甲双胍与二甲双胍+强化生活方式方案，(2)单用二甲双胍与二甲双胍+罗格列酮，以及(3)二甲双胍+强化生活方式方案与二甲双明+罗格列酮。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The TODAY trial is a comparative experiment with the primary objective to compare the efficacy of three treatment arms on time to treatment failure based upon glycemic control in patients enrolled from 10 to 17 years in age with T2DM. The trial will be comprised of three arms. The three treatment group comparisons are: (1) metformin alone versus metformin plus intensive lifestyle program, (2) metformin alone versus metformin plus rosiglitazone, and (3) metformin plus intensive lifestyle program versus metformin plus rosiglitazone.